Cosmo Pharmaceuticals Presents Breakthrough Phase III Results for Breezula (Clascoterone)

I have covered the novel androgen receptor antagonist Breezula® (Clascoterone) for 11 years across numerous posts. The product was originally known as CB-03-01, and manufactured by a company named Cassiopea (Italy). The latter was acquired by Cosmo Pharmaceuticals (Ireland) in December 2021. Clascoterone 5% is expected to get approved in the US and EU as … Continue reading Cosmo Pharmaceuticals Presents Breakthrough Phase III Results for Breezula (Clascoterone)

Breezula Phase 3 Clinical Trials in 50 Locations

There are 50 locations across 4 countries (US, Georgia, Germany and Poland) for Breezula Phase 3 Trials. If you are in the US, please search for your state (or nearby state) in both the SCALP1 and SCALP2 breakouts on this page. Breezula Phase 3 Clinical Trials In my recent post about Cosmo Pharmaceuticals’ update on … Continue reading Breezula Phase 3 Clinical Trials in 50 Locations